Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 11Leukemia, Myeloid, Acute 10Lung Neoplasms 9Myelodysplastic Syndromes 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Multiple Myeloma 5Leukemia, Myelomonocytic, Chronic 5Carcinoma, Non-Small-Cell Lung 5Leukemia, Biphenotypic, Acute 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Pancreatic Neoplasms 3Osteosarcoma 3Mouth Neoplasms 3Lymphoma, T-Cell 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Wilms Tumor 2Thyroid Cancer, Papillary 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Myeloproliferative Disorders 2Mycosis Fungoides 2Melanoma 2

Interventions

Cryosurgery 3nirogacestat 2trifluridine tipiracil drug combination 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Oxaliplatin 1Nivolumab 1Leucovorin 1High-Intensity Focused Ultrasound Ablation 1Fluorouracil 1Embolization, Therapeutic 1Doxorubicin 1Cryotherapy 1Bone Density 1Bevacizumab 1Absorptiometry, Photon 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Desmoid Tumors × X-Rays × Clear all
NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡